The kidneys and hypertension;Nieren und hochdruck

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 37, 2008, Pages 1853-1856

  Hausberg, M ^a   Mann, J ^b   Kühn, Karlwilhelm ^a,c  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^b Klinikum Schwabing   (Germany)

^c NONE   (Germany)

Author keywords

Hypertension; Nephroprotection; Proteinuria; Renal artery stenosis; Renal disease; Sympathetic hyperactivity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT;

ATHEROSCLEROSIS; DOPPLER ECHOGRAPHY; FIBROMUSCULAR DYSPLASIA; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; MORTALITY; PROTEIN RESTRICTION; PROTEINURIA; RENAL PROTECTION; REVIEW; SYMPATHETIC TONE; ADRENERGIC SYSTEM; BALLOON DILATATION; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG ANTAGONISM; GLOMERULUS FILTRATION RATE; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; STENT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BALLOON DILATATION; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY DISEASES; RECEPTORS, ANGIOTENSIN; RENAL ARTERY OBSTRUCTION; RENAL INSUFFICIENCY, CHRONIC; STENTS; SYMPATHETIC NERVOUS SYSTEM;

EID: 51449083787     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082809     Document Type: Review

References (23)

1. Amann K et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1496-1478
2. Böhm M et al. Interdisziplinäres Konsensuspapier zur Renovasopathie mit perkutaner transluminaler Nierenarteriendilatation. Dtsch Med Wschr 2003; 128: 150-156
3. Converse RL et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
4. Hausberg M et al. Sympathetic nerve activity in endstage renal disease. Circulation 2002; 106: 1974-1979
5. Hillege HL et al for the Prevention of Renal and Vascular End Stage Disease(PREVEND)Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
6. Holden A et al. Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. Kidney Int 2006; 70: 948-955
7. Hou T. Efficiacy and safety of benazepril for advanced chronic renal insufficiency. Engl J Med 2006; 354: 131-140
8. Jafar T. Progression of chronic kidney disease: The role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
9. Klahr S et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884
10. Kühn K, Felten H. Hypertonie. In: Risler T, Kühn K (eds) (Hrsg). Facharzt für Nephrologie. München: Elsevier, 2008: 507-542
11. Middeke M. Arterielle Hypertonie. München: Thieme, 2005
12. Neumann J et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576
13. Neumann J et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49: 506-510
14. ONTARGET Investigators. Telmisartan, Ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
15. Ruggenenti P et al. Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN 2). Lancet 2005; 365: 939-947
16. Schlaich MP et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-565
17. Schmidt MW, Schmieder RE. Bewährte und neue Parameter hypertensiver Endorganschäden. Dtsch Med Wschr 2006; 131: H20-H23
18. Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med 2004; 350: 1862-1872
19. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk for macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 703-713
20. Vonend O et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-1717
21. Wright JT et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK-Trial. JAMA 2002; 288: 2421-2431
22. Wright JT et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 2005; 16: 2746-2753
23. Kunz K et al. Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48